Virological markers for clinical trials in chronic viral hepatitis.
| Autor: | Pawlotsky JM; National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hôpital Henri Mondor (AP-HP), Université Paris-Est, Créteil, France.; Team 'Viruses, Hepatology, Cancer', Institut Mondor de Recherche Biomédicale, INSERM U955, Université Paris-Est, Créteil, France. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | JHEP reports : innovation in hepatology [JHEP Rep] 2024 Sep 07; Vol. 6 (11), pp. 101214. Date of Electronic Publication: 2024 Sep 07 (Print Publication: 2024). |
| DOI: | 10.1016/j.jhepr.2024.101214 |
| Abstrakt: | Chronic hepatitis virus infections remain a major public health problem, despite significant therapeutic advances over the past two decades. Considerable progress has been made in the treatment of chronic viral hepatitis, but continued efforts are needed to develop and bring to market new drugs to fill the gaps in the current therapeutic armamentarium. Thus, clinical trials to assess the safety and efficacy of these new therapeutic approaches, including the selection of reliable and objective treatment endpoints, are still needed. Virological biomarkers play an important role in the diagnosis, monitoring, and evaluation of antiviral treatment efficacy. They are often used as primary or secondary endpoints in the evaluation of new treatments for chronic viral hepatitis. However, these markers are not all equally informative. The aim of this review article is to provide a comprehensive overview of the available virological tests for chronic viral hepatitis due to hepatitis B, D, C and E viruses, the information they provide and lack, the specific challenges associated with each, and their use in clinical trials of new treatments. (© 2024 The Author.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|